Evaluation of the Clinical Performance of a Novel Chemiluminescent Immunoassay for Detection of Anticardiolipin and Anti-Beta2-Glycoprotein 1 Antibodies in the Diagnosis of Antiphospholipid Syndrome

AbstractDetection of antiphospholipid antibodies represents the first-line approach for diagnosis of antiphospholipid syndrome (APS). In this study, we evaluated the clinical performance of a novel chemiluminescence assay (CIA) in detection of IgG/IgM/IgA anti-cardiolipin (aCL) and IgG/IgM/IgA anti-&bgr;2 glycoprotein 1 (a&bgr;2GP1) antibodies and to compare it with commercial enzyme-linked immunosorbent assay (ELISA) kits from the same manufacturer.A total of 227 sera were tested in this study, including 84 samples from patients with APS, 104 samples from patients with non-APS diseases as disease controls, and 39 healthy controls. Serum IgG/IgM/IgA aCL and IgG/IgM/IgA a&bgr;2GP1 were determined by both ELISA (QUANTA Lite™ ELISA) and CIA (QUANTA Flash®assays).Significant quantitative correlations were identified between ELISA and CIA in IgG/IgM/IgA aCL and IgG/IgM/IgA a&bgr;2GP1 autoantibodies detection (P < 0.001), with the rho value ranging from 0.51 to 0.87. In addition, ELISA and CIA demonstrated good qualitative agreements in IgG/IgM/IgA aCL and IgM/IgA a&bgr;2GP1 autoantibodies determination with kappa coefficient ranged from 0.52 to 0.77. In contrast, ELISA and CIA showed a moderate qualitative agreement in IgG a&bgr;2GP1 detection with a kappa value of 0.2. Notably, significantly higher IgG a&bgr;2GP1 positive sera were detected by CIA, compared to those detected by ELISA in both primary APS (52.9% vs. 8.8%) and APS associated to other diseases sera (70.0% vs. 8.0%). For diagnosis of APS, IgG a&bgr;2GP1 detection by CIA (IgG a&bgr;2GP1 CIA) demonstrated the highest sensitivity (63.1%), followed by IgG aCL CIA (48.8%). More importantly, IgG a&bgr;2GP1 CIA demonstrated the highest ability to predict the thrombotic events in patients with APS, with an OR of 3 (95% CI: 1.1–7.9).Our data suggest that this novel CIA assay had good performance in detecting aCL and a&bgr;2GP1 antibodies, especially in the detection of IgG a&bgr;2GP1 antibodies. Our findings could shed insight on the application of CIA in the laboratory diagnosis of APS in China.

[1]  P. Simioni,et al.  Detection of IgG anti-Domain I beta2 Glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[2]  L. Punzi,et al.  The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-β2 glycoprotein I antibodies. A comparison with a homemade ELISA method , 2015, Clinical chemistry and laboratory medicine.

[3]  M. Mahler,et al.  Clinical evaluation of a novel chemiluminescent immunoassay for the detection of anti-citrullinated peptide antibodies. , 2014, Clinica chimica acta; international journal of clinical chemistry.

[4]  M. Mahler,et al.  Role of antiphospholipid score and anti-β2-glycoprotein I Domain I autoantibodies in the diagnosis of antiphospholipid syndrome. , 2014, Clinica chimica acta; international journal of clinical chemistry.

[5]  William W. Cohen,et al.  Contribution of anti-β2glycoprotein I IgA antibodies to the diagnosis of anti-phospholipid syndrome: potential interest of target domains to discriminate thrombotic and non-thrombotic patients. , 2014, Rheumatology.

[6]  R. Cervera,et al.  Diagnosis and classification of the antiphospholipid syndrome. , 2014, Journal of autoimmunity.

[7]  Z. Shums,et al.  Evaluation of different immunoassays for the detection of antiphospholipid antibodies: report of a wet workshop during the 13th International Congress on Antiphospholipid Antibodies. , 2014, Clinica chimica acta; international journal of clinical chemistry.

[8]  Ji-Eun Kim,et al.  Clinical performance of anticardiolipin and anti&bgr;2 glycoprotein I antibodies using a new automated chemiluminescent assay: superior thrombotic prediction of combined results measured by two different methods , 2014, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[9]  M. Mahler,et al.  Clinical performance evaluation of a novel rapid response chemiluminescent immunoassay for the detection of autoantibodies to extractable nuclear antigens. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[10]  K. Devreese,et al.  Performance of two new, automated chemiluminescence assay panels for anticardiolipin and anti‐beta2‐glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome , 2012, International journal of laboratory hematology.

[11]  R. Cervera,et al.  Does seronegative antiphospholipid syndrome really exist? , 2012, Autoimmunity reviews.

[12]  K M J Devreese,et al.  Standardization of antiphospholipid antibody assays. Where do we stand? , 2012, Lupus.

[13]  L. Bianchi,et al.  Development and performance evaluation of novel chemiluminescence assays for detection of anti-PR3 and anti-MPO antibodies. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[14]  K. Devreese,et al.  Evaluation of a new set of automated chemiluminescense assays for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome. , 2011, Thrombosis research.

[15]  P. Meroni,et al.  Pathogenesis of antiphospholipid syndrome: understanding the antibodies , 2011, Nature Reviews Rheumatology.

[16]  M. Petri,et al.  ‘Non-criteria’ aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010 , 2011, Lupus.

[17]  J. Musial,et al.  Analytical and clinical performance of a new, automated assay panel for the diagnosis of antiphospholipid syndrome , 2010, Journal of thrombosis and haemostasis : JTH.

[18]  A. Ruffatti,et al.  Influence of different IgG anticardiolipin antibody cut‐off values on antiphospholipid syndrome classification , 2008, Journal of thrombosis and haemostasis : JTH.

[19]  S. Pierangeli,et al.  A Quarter of a Century in Anticardiolipin Antibody Testing and Attempted Standardization Has Led Us to Here, which Is? , 2008, Seminars in thrombosis and hemostasis.

[20]  Y. Shoenfeld,et al.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) , 2006, Journal of thrombosis and haemostasis : JTH.